Therapeutic Antibodies – News and Features

Georgia Tech researchers created AF2Complex, a deep-learning tool that predicts antibody interactions with proteins, enhancing immunotherapy development. The model accurately identified effective antibodies against Covid-19.

Caltech scientists have created a method to design antibodies that specifically recognize the cancer-causing mutant HER2 protein. This biologic could lead to effective therapies for patients with HER2 mutations.

The first randomized clinical trial on monoclonal antibodies' impact on long COVID found that the combination of amubarvimab and romlusevimab did not decrease long COVID symptoms.

Researchers have discovered that combining immunotherapy and chemotherapy can overcome treatment resistance in a subset of lung cancer patients.

This article explores the revolution in new drug modalities and the challenges around effective data strategies to support AI efforts.

Bioprocessing involves the production of a high-value-added product from a living source. In this article, the stages of bioprocessing are described, with a focus on the central piece of this concept: the bioreactor.

Researchers found that the immunotherapy drug pembrolizumab significantly extends the cancer-free period for patients with high-risk muscle-invasive bladder cancer after surgery.

Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients with advanced solid cancers.

The DESTINY-Breast12 trial revealed that trastuzumab deruxtecan (T-DXd) effectively targets brain metastases in HER2-positive breast cancer. T-DXd offers a promising new option for patients with advanced disease.

A study challenges the amyloid plaque theory in Alzheimer’s, showing that increased levels of the brain protein Aβ42 are as strongly correlated with slower cognitive decline as reductions in amyloid plaques.